GlassScriptPhysician profile
Skye A Gratton
NPI 1114165370
$3,099.57
in general payments reported to CMS, 2019-2025
12 companies · $372 in 2025
The $372 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $612 · 2022: $401 · 2023: $610 · 2024: $1,104 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,086.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,283.78 | 2021-2024 | Xarelto |
| Inari Medical, INC. | $321.05 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Ceribell, INC. | $258.17 | 2024-2025 | Pocket Eeg Device |
| Boston Scientific Corporation | $254.68 | 2022-2025 | Enroute Transcarotid Neuroprotection System |
| Abbvie INC. | $242.66 | 2022-2024 | |
| Janssen Scientific Affairs, LLC | $204.38 | 2024 | Xarelto |
| Chiesi USA, INC. | $186.49 | 2024-2025 | Cleviprex |
| Silk Road Medical, INC. | $139.34 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Gilead Sciences, INC. | $125.00 | 2024 | Veklury |
| Stryker Corporation | $40.29 | 2025 | Artix Mt |
| Pfizer INC. | $22.40 | 2021 | |
| Biosense Webster, INC. | $21.33 | 2023 | Carto 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Skye Gratton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.